AVO’s goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the worldrenowned CERN. In the past 18 months, the project has been de-risked through important technical milestones. AVO is working on the verification and validation phase, prior to CE marking and LIGHT being used on the first patients. Proposed changes to the US reimbursement framework are beneficial to PBT as a whole, and the trend towards hypo-fractionation of ultra-high doses in a single patient visit (FLASH), for which LIGHT is uniquely positioned to deliver.
11 Nov 2019
FLASH benefits from new US reimbursement
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
FLASH benefits from new US reimbursement
Advanced Oncotherapy Plc (AVO:LON) | 1.9 0 0.0% | Mkt Cap: 10.4m
- Published:
11 Nov 2019 -
Author:
Martin Hall -
Pages:
24
AVO’s goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the worldrenowned CERN. In the past 18 months, the project has been de-risked through important technical milestones. AVO is working on the verification and validation phase, prior to CE marking and LIGHT being used on the first patients. Proposed changes to the US reimbursement framework are beneficial to PBT as a whole, and the trend towards hypo-fractionation of ultra-high doses in a single patient visit (FLASH), for which LIGHT is uniquely positioned to deliver.